HomeComparePHAS vs PEP

PHAS vs PEP: Dividend Comparison 2026

PHAS yields 2853.07% · PEP yields 3.63%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PHAS wins by $281872346866.90M in total portfolio value
10 years
PHAS
PHAS
● Live price
2853.07%
Share price
$0.07
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$281872346867.04M
Annual income
$263,691,193,706,389,300.00
Full PHAS calculator →
PEP
PepsiCo Inc.
● Live price
3.63%
Share price
$156.82
Annual div
$5.69
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$141.9K
Annual income
$61,875.67
Full PEP calculator →

Portfolio growth — PHAS vs PEP

📍 PHAS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPHASPEP
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PHAS + PEP cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PHAS pays
PEP pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PHAS
Annual income on $10K today (after 15% tax)
$242,510.70/yr
After 10yr DRIP, annual income (after tax)
$224,137,514,650,430,900.00/yr
PEP
Annual income on $10K today (after 15% tax)
$308.41/yr
After 10yr DRIP, annual income (after tax)
$52,594.32/yr
At 15% tax rate, PHAS beats the other by $224,137,514,650,378,300.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PHAS + PEP for your $10,000?

PHAS: 50%PEP: 50%
100% PEP50/50100% PHAS
Portfolio after 10yr
$140936173433.59M
Annual income
$131,845,596,853,225,600.00/yr
Blended yield
93.55%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PEP right now

PHAS
Analyst Ratings
3
Buy
3
Hold
Consensus: Buy
PEP
Analyst Ratings
1
Strong
15
Buy
27
Hold
1
Sell
Consensus: Hold
Price Target
$172.43
+10.0% upside vs current
Range: $156.00 — $191.00
Altman Z
3.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PHAS buys
0
PEP buys
0
No recent congressional trades found for PHAS or PEP in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPHASPEP
Forward yield2853.07%3.63%
Annual dividend / share$2.00$5.69
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$281872346867.04M$141.9K
Annual income after 10y$263,691,193,706,389,300.00$61,875.67
Total dividends collected$280611873155.80M$123.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyHold

Year-by-year: PHAS vs PEP ($10,000, DRIP)

YearPHAS PortfolioPHAS Income/yrPEP PortfolioPEP Income/yrGap
1← crossover$296,007$285,306.70$10,849$509.42+$285.2KPHAS
2$8,209,503$7,892,775.47$11,969$750.47+$8.20MPHAS
3$213,363,270$204,579,102.60$13,500$1,124.14+$213.35MPHAS
4$5,197,428,076$4,969,129,376.72$15,680$1,721.66+$5197.41MPHAS
5$118,688,009,645$113,126,761,603.35$18,929$2,715.34+$118687.99MPHAS
6$2,541,344,545,416$2,414,348,375,096.37$24,023$4,450.80+$2541344.52MPHAS
7$51,033,223,710,004$48,313,985,046,408.66$32,510$7,669.92+$51033223.68MPHAS
8$961,336,701,807,468$906,731,152,437,763.20$47,709$14,093.60+$961336701.76MPHAS
9$16,991,731,925,840,448$15,963,101,654,906,456.00$77,415$28,083.48+$16991731925.76MPHAS
10$281,872,346,867,038,600$263,691,193,706,389,300.00$141,922$61,875.67+$281872346866.90MPHAS

PHAS vs PEP: Complete Analysis 2026

PHASStock

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Full PHAS Calculator →

PEPConsumer Staples

PepsiCo, Inc. manufactures, markets, distributes, and sells various beverages and convenient foods worldwide. The company operates through seven segments: Frito-Lay North America; Quaker Foods North America; PepsiCo Beverages North America; Latin America; Europe; Africa, Middle East and South Asia; and Asia Pacific, Australia and New Zealand and China Region. It provides dips, cheese-flavored snacks, and spreads, as well as corn, potato, and tortilla chips; cereals, rice, pasta, mixes and syrups, granola bars, grits, oatmeal, rice cakes, simply granola, and side dishes; beverage concentrates, fountain syrups, and finished goods; ready-to-drink tea, coffee, and juices; dairy products; and sparkling water makers and related products. It serves wholesale and other distributors, foodservice customers, grocery stores, drug stores, convenience stores, discount/dollar stores, mass merchandisers, membership stores, hard discounters, e-commerce retailers and authorized independent bottlers, and others through a network of direct-store-delivery, customer warehouse, and distributor networks, as well as directly to consumers through e-commerce platforms and retailers. The company was founded in 1898 and is headquartered in Purchase, New York.

Full PEP Calculator →
📬

Get this PHAS vs PEP comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PHAS vs SCHDPHAS vs JEPIPHAS vs OPHAS vs KOPHAS vs MAINPHAS vs MOPHAS vs PMPHAS vs GIS

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.